Non Hodgkin's Lymphoma
Conditions
Keywords
Lenalidomide, Rituximab, untreated indolent Non-Hodgkin's Lymphoma
Brief summary
Lenalidomide has been shown to have single agent activity in indolent Non-Hodgkin's Lymphoma. It is approved for the treatment of multiple myeloma and myelodysplastic syndrome. Rituximab is effective as a single agent and in combination with chemotherapy for indolent Non-Hodgkin's Lymphoma. The purpose of this study is to see how well giving lenalidomide together with rituximab works in treating patients with previously untreated indolent Non Hodgkin's Lymphoma. Lenalidomide will taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, unacceptable side effects or after twelve cycles if the patient is responding well. Rituximab 375 mg/m2/wk x 4 weeks will begin on Day 15 of cycle 1. After 4 cycles of therapy, if patients respond well to treatment, patients will receive a second course of Rituximab. Blood samples will be collected to assess how the immune system is functioning.
Interventions
DRUGRituximab
Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.
DRUGLenalidomide
Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment.
Sponsors
Celgene
University of California, Davis
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. All patients must be informed of the investigative nature of the clinical trial and given written informed consent in accordance with institutional and federal guidelines. 2. Age greater than or equal to 18 years at the time of signing the informed consent form. 3. Able to adhere to the study visit schedule and other protocol requirements. 4. Previously untreated, histologically confirmed indolent lymphoma including follicle cell lymphoma, WHO classification, grade I or II, and marginal zone lymphoma. Bone marrow biopsies as the sole means of diagnosis are not acceptable, but they may be submitted in conjunction with nodal biopsies. Fine needle aspirates are not acceptable. 5. At least one measurable lesion according to the International Working Group Response criteria for lymphomas. There must be measurable lymphadenopathy to follow with serial exam and/or imaging. 6. Submission of original biopsy for review by local staff hematopathologist. 7. ECOG performance status of 0 -2 at study entry. 8. No major organ dysfunction with laboratory test results within these ranges: * Absolute neutrophil count greater than or equal to 1000 /uL * Platelet count greater than or equal to 75 x 109/L * Total bilirubin less than or equal to 2.0 mg/dL. * HIV negative * Subjects must have calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault formula. See section below, Dosing Regimen, regarding lenalidomide dose adjustment for calculated creatinine clearance ≥ 30ml/min and \< 60ml/min. 9. Life expectancy of greater than 3 months. 10. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. 11. Disease free of prior malignancies for greater than or equal to 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast 12. Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation. (patients who are intolerant to aspirin may use low molecular weight heparin). 13. Must be able to swallow lenalidomide capsules.
Exclusion criteria
1. Any prior treatment for Non-Hodgkin's Lymphoma. 2. Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. 3. Pregnant or breast-feeding females. (Lactating females must agree not to breast feed while taking lenalidomide). 4. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study. 5. Use of any other experimental drug or therapy within 28 days of baseline. 6. Known hypersensitivity to thalidomide or rituximab. 7. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. 8. Any prior use of lenalidomide. 9. Concurrent use of other anti-cancer agents or treatments. 10. Known positive for HIV 11. Known active hepatitis, type A, B or C. 12. Evidence for CNS metastatic disease 13. Subjects with ≥ Grade 2 neuropathy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Response Rate to Treatment | 4 months | Responses will be assessed by the Revised Working Group Response Criteria for Malignant Lymphoma. A complete response is the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. A partial response is regression of measurable disease and no new sites of disease. Stable disease is failure to attain a complete response/partial response or progressive disease. Response Rate defined as the proportion of patients whose best response was complete response (CR; confirmed or unconfirmed) or partial response (PR). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Time to Next Treatment. | Up to about 13 years. | Time from when the patient started treatment to the time the patient receives next treatment. |
| Overall Survival | Up to about 13 years | Median overall survival measured as the time from start of treatment to the date of death or the last date the patient was known to be alive. |
| Number of Patients Experiencing Treatment-related Adverse Events. | Up to about 12 years. | Defined as the number of patients experiencing treatment-related adverse events as graded according to the National Cancer Institute Common Toxicity Criteria Version (NCI CTCAE) 4.0. |
| Duration of Response From Start of Therapy | Up to 14 months. | The duration of response is measured from the time measurement criteria are met for complete response/partial response(whichever status is recorded first) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The duration of response is measured from the time measurement criteria are first met for complete response until the first date that recurrent disease is objectively documented. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Lenalidomide + Rituximab Patients will receive lenalidomide 20 mg daily (oral), on days 1-21 of a 28 day cycle. Rituximab 375 mg/m2 (into the vein) will be administered weekly for 4 doses starting day 15 of cycle 1, to be repeated if patient does not achieve a complete response after cycle 4, on days 1, 8, 15 and 22 of cycle 5.
Rituximab: Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.
Lenalidomide: Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment. | 30 |
| Total | 30 |
Baseline characteristics
| Characteristic | Lenalidomide + Rituximab |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 13 Participants |
| Age, Categorical Between 18 and 65 years | 17 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 28 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Region of Enrollment United States | 30 participants |
| Sex: Female, Male Female | 16 Participants |
| Sex: Female, Male Male | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 30 |
| other Total, other adverse events | 30 / 30 |
| serious Total, serious adverse events | 1 / 30 |
Outcome results
Primary
Response Rate to Treatment
Responses will be assessed by the Revised Working Group Response Criteria for Malignant Lymphoma. A complete response is the complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. A partial response is regression of measurable disease and no new sites of disease. Stable disease is failure to attain a complete response/partial response or progressive disease. Response Rate defined as the proportion of patients whose best response was complete response (CR; confirmed or unconfirmed) or partial response (PR).
Time frame: 4 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lenalidomide + Rituximab | Response Rate to Treatment | 0.82 proportion of patients with CR or PR |
Secondary
Duration of Response From Start of Therapy
The duration of response is measured from the time measurement criteria are met for complete response/partial response(whichever status is recorded first) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The duration of response is measured from the time measurement criteria are first met for complete response until the first date that recurrent disease is objectively documented.
Time frame: Up to 14 months.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Lenalidomide + Rituximab | Duration of Response From Start of Therapy | 2 months |
Secondary
Number of Patients Experiencing Treatment-related Adverse Events.
Defined as the number of patients experiencing treatment-related adverse events as graded according to the National Cancer Institute Common Toxicity Criteria Version (NCI CTCAE) 4.0.
Time frame: Up to about 12 years.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Lenalidomide + Rituximab | Number of Patients Experiencing Treatment-related Adverse Events. | 28 participants |
Secondary
Overall Survival
Median overall survival measured as the time from start of treatment to the date of death or the last date the patient was known to be alive.
Time frame: Up to about 13 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Lenalidomide + Rituximab | Overall Survival | NA months |
Secondary
Time to Next Treatment.
Time from when the patient started treatment to the time the patient receives next treatment.
Time frame: Up to about 13 years.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Lenalidomide + Rituximab | Time to Next Treatment. | 97.8 months |